A Phase IIa Study of TAS-205 for Duchenne Muscular Dystrophy

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

May 15, 2017

Study Completion Date

October 17, 2017

Conditions
Duchenne Muscular Dystrophy
Interventions
DRUG

TAS-205

2 groups: Low dose group, High dose group. Oral administration for 24 weeks, bis in die (BID) after meal

DRUG

Placebo

1 group: Placebo group. Oral administration for 24 weeks, BID after meal

Trial Locations (11)

467-8601

Nagoya City University Hospital, Aichi

502-8558

National Hospital Organization Nagara Medical Center, Gifu

650-0017

Kobe University Hospital, Hyōgo

616-8255

National Hospital Organization Utano Hospital, Kyoto

390-8621

Shinshu University Hospital, Nagano

945-8585

National Hospital Organization Niigata National Hospital, Niigata

560-8552

National Hospital Organization Toneyama National Hospital, Osaka

349-0196

National Hospital Organization Higashisaitama Hospital, Saitama

162-8666

Tokyo Women's Medical University Hospital, Tokyo

187-8551

National Center of Neurology and Psychiatry, Tokyo

683-8504

Tottori University Hospital, Tottori

All Listed Sponsors
lead

Taiho Pharmaceutical Co., Ltd.

INDUSTRY

NCT02752048 - A Phase IIa Study of TAS-205 for Duchenne Muscular Dystrophy | Biotech Hunter | Biotech Hunter